Eiger Mountains
Keyword Search
 
2019 | 2018 | 2017 | 2016
DateTitle 
12/12/16Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia (PBH)
-- Positive Interim Data from Phase 2 Multiple-Ascending Dose Study -- Novel Liquid Formulation of Exendin 9-39 -- US Orphan Designation for Hyperinsulinemic Hypoglycemia PALO ALTO, Calif., Dec. 12, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, today announced clinical and regulatory advances in the development of exendin 9-39 for the treatment of post-bariatric hypoglycemia (PBH).  ... 
Printer Friendly Version
11/29/16Eiger Updates Progress in Clinical Development Program for Exendin 9-39 to Treat Post-Bariatric Hypoglycemia (PBH)
- Exendin 9-39 investigational new drug (IND) application filed - PBH Analyst / Key Opinion Leader Event planned December 9th - Multiple-ascending dose (MAD) study interim data to be presented PALO ALTO, Calif., Nov. 29, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, today announced an update on the Company's development program for exendin 9-39 as a potential treatment for post-baria... 
Printer Friendly Version
11/21/16Eiger BioPharmaceuticals to Participate in Two Investor Conferences in November 2016
PALO ALTO, Calif., Nov. 21, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a clinical stage biopharmaceuticals company focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will participate in two upcoming investor conferences in November 2016, providing a corporate overview and business update in group and individual meetings. 2016 Oppenheimer Life Sciences Summit, Sofitel ... 
Printer Friendly Version
11/14/16Eiger Announces Additional LOWR HDV Program Data, Clinical and Regulatory Plans at the American Association for the Study of Liver Diseases (AASLD) Meeting
- Update on Data Presented and Analyst Meeting through Monday Evening PALO ALTO, Calif., Nov. 14, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc, (NASDAQ: EIGR) today announced presentation of additional data from the LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program presented today at the American Association for the Study of Liver Diseases (AASLD) meeting in Boston, Massachusetts. The Company hosted a review of key findings from the LOWR HDV Program with HDV key op... 
Printer Friendly Version
11/14/16Eiger Announces Positive Phase 2 Data at the American Association for the Study of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified with Lonafarnib Therapy in LOWR HDV Program
- Data Presented through Monday Morning PALO ALTO, Calif., Nov. 14, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc, (NASDAQ: EIGR) today announced an update on presentations of data from its LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program presented as of today at the American Association for the Study of Liver Diseases (AASLD) meeting in Boston, Massachusetts. LOWR HDV is a multi-center, international Phase 2 program designed to identify optimal dosing of lonafarni... 
Printer Friendly Version
11/08/16Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results
- Data from Multi-center, International LOWR HDV (LOnafarnib With Ritonavir in HDV) Phase 2 Program to be Presented at AASLD 2016 - Eiger Hosted LOWR HDV Program Key Opinion Leader Review at AASLD 2016 - Four Product Candidates in Four Orphan Indications Continuing to Advance PALO ALTO, Calif., Nov. 8, 2016 Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today a business update and finan... 
Printer Friendly Version
10/24/16Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign to Expand Awareness and Testing for HDV Infection
- Collaboration with ARUP Laboratories and Hepatitis B Foundation - HDV viral load assay now available in U.S. PALO ALTO, Calif., Oct. 24, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced the launch of a nationwide hepatitis delta (HDV) campaign to expand patient access to testing and raise awareness of HDV co-infection in ... 
Printer Friendly Version
10/19/16Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus (HDV) Infection
- LIMT HDV: Lambda Interferon MonoTherapy in HDV Study PALO ALTO, Calif., Oct. 19, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that the first patient was dosed in the Phase 2 LIMT HDV (Lambda Interferon MonoTherapy in HDV) study, a monotherapy trial of pegylated interferon lambda 1a ("Lambda") as a potential treatment for chronic hepatitis D virus (HDV) infection.... 
Printer Friendly Version
10/17/16Eiger Announces Orphan Designation of Exendin 9-39 for Treatment of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) from European Medicines Agency (EMA)
PALO ALTO, Calif., Oct. 17, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today that the European Medicines Agency (EMA) has granted orphan designation to exendin 9-39 for the treatment of non-insulinoma pancreatogenous hypoglycemia syndrome (NIPHS).  NIPHS describes a spectrum of acquired metabolic disorders characterized by inappropriately high insulin levels (hyperinsulinemia) and l... 
Printer Friendly Version
10/13/16Eiger Announces Abstracts and Presentations of LOWR HDV Program at the American Association for the Study of Liver Diseases (AASLD) Meeting
PALO ALTO, Calif., October 13, 2016 — Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that abstracts from its LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program will be presented at the American Association for the Study of Liver Diseases (AASLD) meeting in Boston, Massachusetts, November 11 to 15, 2016. Twenty-four-week data from the phase 2 LOWR HDV Program will be presented. Accepted AASLD abstracts are listed below: Yurdaydin, C. et al; “Explori... 
Printer Friendly Version
09/07/16Eiger Announces Completion of Dosing in Phase 2 LOWR HDV - 4 Study at Hannover Medical School
PALO ALTO, Calif., Sept. 7, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced the completion of dosing of LOWR HDV – 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus – 4) at Hannover Medical School in Hannover, Germany.  LOWR HDV – 4 is a 15 patient, 24-week open-label study designed to evaluate the efficacy and tolerability o... 
Printer Friendly Version
09/06/16Eiger BioPharmaceuticals to Present at the BioCentury NewsMakers in the Biotech Industry Conference on September 9th
PALO ALTO, Calif., Sept. 6, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at the BioCentury 23rd Annual NewsMakers in the Biotech Industry Conference on Friday, September 9, 2016 at 3:30 pm ET at the Millennium Broadway Hotel &... 
Printer Friendly Version
09/01/16Eiger BioPharmaceuticals to Present at the 5th Annual Liolios Gateway Conference on September 7, 2016
PALO ALTO, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) has been invited to present at the 2016 Gateway Conference being held on September 7-8, 2016 at the Four Seasons Hotel San Francisco. Eiger BioPharmaceuticals management is scheduled to present on Wednesday, September 7 at 1:30 p.m. Pacific time, with one-on-one meetings held throughout the conference. The presentation will be webcast live and available for replay in the Investor Relations se... 
Printer Friendly Version
08/18/16Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock
PALO ALTO, Calif., Aug. 18, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced the pricing of its underwritten public offering of 1,250,000 shares of its common stock at a price to the public of $16.00 per share, before underwriting discounts and commissions.  All of the shares of common stock to be sold in the offering are to be so... 
Printer Friendly Version
08/17/16Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
PALO ALTO, Calif., Aug. 17, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.  Eiger intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock ... 
Printer Friendly Version
08/10/16Eiger BioPharmaceuticals Reports Second Quarter 2016 Financial Results
- Four Product Candidates in Four Orphan Indications Advancing Toward Near-Term Milestones PALO ALTO, Calif., Aug. 10, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today a business update and financial results for the three months and six months ended June 30, 2016.     "Eiger has made significant progress in 2016 in advancing our pipeline of novel products for the... 
Printer Friendly Version
08/08/16Eiger BioPharmaceuticals to Present at the 2016 Wedbush PacGrow Healthcare Conference on August 17th
PALO ALTO, Calif., Aug. 8, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at the 2016 Wedbush PacGrow Healthcare Conference on Wednesday, August 17, 2016 at 3:05 pm ET at Le Parker Meridien Hotel in New York City. A live webcast of the presentation will be available on... 
Printer Friendly Version
07/25/16Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema
Novel first-in-class inhibitor of LTB(4) production targeting disease modification PALO ALTO, Calif., July 25, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that the first patient in the Phase 2 ULTRA study was dosed at Stanford University.  The ULTRA study will evaluate the effects of ubenimex in patients with secondary lymphedema of the lower limb(s) who are optim... 
Printer Friendly Version
07/18/16Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension
Novel first-in-class inhibitor of LTB(4) targeting disease modification PALO ALTO, Calif., July 18, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that the first patient was dosed in the Phase 2 LIBERTY study.  The LIBERTY study will evaluate the effects of ubenimex added to current standard of care in patients with pulmonary arterial hypertension (PAH).  Despite mul... 
Printer Friendly Version
07/06/16Eiger BioPharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 12th
PALO ALTO, Calif., July 6, 2016 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at the Cantor Fitzgerald 2nd Annual Healthcare Conference on Tuesday, July 12, 2016 at 9:00 am ET at Le Parker Meridien Hotel in New York City.A live webcast of the presentation will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com, under the "Investors" tab... 
Printer Friendly Version
06/13/16Eiger Announces Positive Clinical Results of Single Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Post-Bariatric Hypoglycemia
Oral Presentation at American Diabetes Association Meeting in New Orleans, LA PALO ALTO, Calif., June 13, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the presentation of positive results of a study evaluating subcutaneously administered exendin (9-39) in post-bariatric surgical patients who experience dangerously low, postprandial blood glucose levels (hypoglycemia) known ... 
Printer Friendly Version
05/16/16Eiger BioPharmaceuticals Provides Corporate Update and Reports First Quarter 2016 Financial Results
PALO ALTO, Calif., May 16, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today a business update and financial results for the three months ended March 31, 2016.     Recent Corporate Highlights In May, Eiger reported first patient dosed in a Phase 2 multiple ascending dose study of subcutaneous exendin (9-39) in patients with hypoglycemia post-gastric bypass surgery... 
Printer Friendly Version
05/10/16Eiger Announces First Patient Dosed in Phase 2 Multiple Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Hypoglycemia Post-Gastric Bypass Surgery
Novel first-in-class GLP-1 antagonist targeted for rare hypoglycemic condition PALO ALTO, Calif., May 10, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that the first patient has been dosed in a Phase 2 study to evaluate subcutaneously administered exendin (9-39) in patients who experience dangerously low blood glucose levels (hypoglycemia) after undergoing gastric ... 
Printer Friendly Version
05/03/16Eiger Bio Strengthens Senior Management Team with Announcement of Debra Odink, PhD as Senior Vice President of Technical Operations
PALO ALTO, Calif., May 3, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a biopharmaceutical company focused on the development and commercialization of targeted therapies for Orphan diseases, announced today the appointment of Debra Odink, PhD as the Company's Senior Vice President of Technical Operations. "This year, Eiger plans to dose patients in eight different Phase 2 clinical studies in four diverse orphan therapeutic programs across international sites involving... 
Printer Friendly Version
04/20/16Eiger BioPharmaceuticals Announces License of Worldwide Rights to Pegylated Interferon Lambda-1a from Bristol-Myers Squibb
Including Rights for All Indications and Associated Patents PALO ALTO, Calif., April 20, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) announced today that it has licensed Pegylated Interferon Lambda-1a ("Lambda"), a novel, well-characterized, first in class Type III interferon to be studied as an investigational therapy for hepatitis delta virus (HDV) infection, from Bristol-Myers Squibb.  Lambda has been administered in clinical trials involving over 3,000 subjects.  ... 
Printer Friendly Version
04/04/16Eiger BioPharmaceuticals Strengthens Board of Directors with Addition of Industry Veteran Charles J. "Chuck" Bramlage
PALO ALTO, Calif., April 4, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc, (NASDAQ:  EIGR) announced today that its Board of Directors has appointed Charles J. "Chuck" Bramlage as a member of the Board. Mr. Bramlage is a pharmaceutical industry veteran with extensive experience in marketing, sales, and corporate operations spanning large pharma to start up pharma.  He is currently the Chief Executive Officer of Pearl Therapeutics, Inc., a development stage start-up company focused on t... 
Printer Friendly Version
03/30/16Eiger BioPharmaceuticals Announces Abstracts and Presentations of Lonafarnib Data in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Meeting
PALO ALTO, Calif., March 30, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc, (NASDAQ:  EIGR) today announced that abstracts from its Hepatitis Delta Virus (HDV) development program will be presented at the European Association for the Study of the Liver (EASL) meeting in Barcelona, Spain, April 13 to 17, 2016.  In addition, interim data from the LOWR HDV – 2 (LOnafarnib With Ritonavir in Hepatitis Delta Virus – 2) Phase 2 study in patients infected with HDV will be presented for the first ti... 
Printer Friendly Version
03/28/16Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation for Ubenimex in Pulmonary Arterial Hypertension by European Medicines Agency
PALO ALTO, Calif., March 28, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) today announced that the European Medicines Agency (EMA) has granted Orphan Medicinal Product status to ubenimex for the treatment of pulmonary arterial hypertension (PAH). "We are very pleased with the EMA Committee of Orphan Medicinal Products (COMP) designation of orphan status for ubenimex in PAH," said Joanne Quan, MD, Chief Medical Officer at Eiger. "We will soon begin enrolling the LIBERTY... 
Printer Friendly Version
03/22/16Eiger BioPharmaceuticals Closes Merger With Celladon
Renamed Eiger and New Trading Symbol (NASD: EIGR, as of March 23) Developing a Clinical Stage Pipeline of Orphan Disease Programs PALO ALTO, Calif., March 22, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASD: EIGR) today announced completion of its merger with Celladon Corporation effective March 22, 2016. In connection with the merger, Celladon changed its name to Eiger BioPharmaceuticals, Inc. The combined compa... 
Printer Friendly Version